Amjevita Injection
Product Images NDC 72511-400

Product Visual Gallery

This gallery contains 40 technical images submitted to the FDA as part of the official labeling for Amjevita (NDC 72511-400). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Amjevita 01)

A line graph depicting the percent of ACR 20 responders over time (weeks) for two groups: one receiving 40 mg of adalimumab-atto every other week and a placebo group. The 40 mg treatment line shows a rapid increase and higher sustained response compared to the placebo over a 48-week period.*

FDA Label Image

Figure 2 (Amjevita 02)

A line graph depicting the percentage of ASAS 20 response over 26 weeks for two groups: one treated with Adalimumab (N=208) and the other with placebo (N=107). The graph shows time in weeks on the x-axis and percent response on the y-axis, illustrating a higher and sustained response rate in the Adalimumab group compared to placebo over the study period.*

FDA Label Image

Image (Amjevita 03)

An instructional illustration of the AMJEVITA prefilled autoinjector pen for subcutaneous injection. It highlights the blue start button at the top, the location for the expiration date, a window displaying the medicine inside, and a yellow cap on the bottom. The pen's design elements are labeled to guide proper use.*

FDA Label Image

Image (Amjevita 04)

An illustrated diagram of an AMJEVITA injection pen showing labeled parts: expiration date at the top, a yellow window indicating injection completion, a yellow safety guard, and a yellow cap removed at the bottom. The pen is primarily blue with white and yellow accents, corresponding to the adalimumab-atto injection device.*

FDA Label Image

Image (Amjevita 05)

An instructional diagram of an AMJEVITA injection pen with a yellow cap. The image highlights the yellow cap, a window on the pen showing the medicine inside, and indicates the presence of the medicine within the pen device.*

FDA Label Image

Image (Amjevita 06)

Illustration showing the contents of an AMJEVITA injection kit, including a blue injection pen, alcohol wipes, cotton balls, an adhesive bandage, and a red sharps disposal container with biohazard symbol.*

FDA Label Image

Image (Amjevita 07)

An instructional diagram showing appropriate subcutaneous injection sites on a human body. The diagram highlights the stomach area (abdomen) and the front thighs as preferred injection locations for administering the injection.*

FDA Label Image

Image (Amjevita 08)

An instructional illustration showing hands preparing an AMJEVITA (adalimumab-atto) injection pen by removing the yellow cap from the pen before subcutaneous administration.*

FDA Label Image

Image (Amjevita 09)

An instructional illustration showing a person's hand pinching skin on the front of the thigh. Two arrows indicate the direction of the skin pinch, suggesting how to prepare the injection site for a subcutaneous injection.*

FDA Label Image

Image (Amjevita 10)

AMJEVITA 40 mg/.4 mL subcutaneous injection carton label. The label prominently displays the proprietary name AMJEVITA in green, with the generic name adalimumab-atto underneath. The dosage strength is 40 mg/.4 mL. The label also includes usage and storage instructions, manufacturer information (Amgen USA Inc.), and several regulatory compliance logos and marks.*

FDA Label Image

Image (Amjevita 11)

An instructional illustration demonstrating subcutaneous injection technique, showing a person pinching abdominal skin with one hand while preparing to inject with the other hand. This image is consistent with instructions for administering AMJEVITA (adalimumab-atto) injection subcutaneously.*

FDA Label Image

Image (Amjevita 12)

An instructional illustration showing the proper method of holding an injection pen device at a 90-degree angle to the skin, preparing for a subcutaneous injection of AMJEVITA (adalimumab-atto). The visual emphasizes hand positioning and injection angle on the skin's surface.*

FDA Label Image

Image (Amjevita 13)

An instructional illustration showing hands holding an injection pen at a 90-degree angle to the skin, demonstrating subcutaneous administration technique for AMJEVITA adalimumab-atto injection.*

FDA Label Image

Image (Amjevita 14)

An illustration diagram showing a downward black arrow pointing within a circular cutout area on a blue and beige background, likely part of an instructional graphic for a subcutaneous injection device or packaging related to AMJEVITA (adalimumab-atto).*

FDA Label Image

Image (Amjevita 15)

An instructional illustration depicting the use of an AMJEVITA injection pen for subcutaneous administration. It shows one hand holding the pen vertically against the skin of the abdomen, with another hand stabilizing the area. A "click" sound is indicated, representing the activation of the injection device.*

FDA Label Image

Image (Amjevita 16)

An instructional illustration showing a hand holding and pressing the Amjevita injection device against the skin while the other hand stabilizes the injection area, indicating the administration of a subcutaneous injection with a 'click' sound effect.*

FDA Label Image

Image (Amjevita 17)

An illustration showing a timer set to approximately 10 seconds next to an injection device window indicating medication within the device, likely demonstrating the wait time after injecting AMJEVITA (adalimumab-atto) subcutaneously before removing the device.*

FDA Label Image

Image (Amjevita 18)

FDA Label Image

Image (Amjevita 19)

An instructional illustration showing a hand disposing of a used injection pen into a red biohazard sharps container with a black biohazard symbol and an open lid. A black arrow indicates the pen being placed into the container.*

FDA Label Image

Image (Amjevita 20)

An instructional diagram of a blue injection pen labeled with parts including a blue start button at the top, an expiration date below it, a window showing the medicine inside, and a yellow cap on the bottom. This pen is consistent with the design of subcutaneous injection devices like AMJEVITA (adalimumab-atto).*

FDA Label Image

Image (Amjevita 21)

An instructional illustration depicting a human figure highlighting recommended subcutaneous injection sites for AMJEVITA (adalimumab-atto). The labeled injection areas include the stomach (abdomen) and the thigh.*

FDA Label Image

Image (Amjevita 22)

Instructional illustration showing two subcutaneous injection sites for AMJEVITA (adalimumab-atto) injection. One image depicts an injection being administered into the thigh, while the other shows injection into the abdomen. Both demonstrate proper injection technique with a syringe.*

FDA Label Image

Image (Amjevita 23)

An instructional illustration showing hands preparing a subcutaneous injection using a prefilled syringe pen with a removable yellow safety cap, as part of administering the AMJEVITA (adalimumab-atto) injection.*

FDA Label Image

Image (Amjevita 24)

An instructional illustration showing how to administer a subcutaneous injection using a syringe or pen. The top part depicts pressing down a blue button or cap, while the lower part shows a hand holding the device and injecting it into the skin of the forearm or leg area. Text beneath reads 'Push down.'*

FDA Label Image

Image (Amjevita 25)

An instructional illustration showing the use of an injection pen. It depicts a hand pressing the pen against the skin to administer a subcutaneous injection, indicated by the word "click" to signify activation of the device.*

FDA Label Image

Image (Amjevita 26)

An instructional illustration showing the steps for subcutaneous injection using a pen device. The image includes a timer indicating a 15-second wait, a close-up of the injection window on the pen showing a yellow indicator, and hands administering the injection with a 'click' sound denoted at the start of the injection.*

FDA Label Image

Image (Amjevita 27)

Illustration of a subcutaneous injection syringe labeled with parts including plunger rod, finger flange, label and expiration date area, syringe barrel containing medicine, and needle cap on the bottom. The diagram visually identifies key components of the syringe used for administering AMJEVITA (adalimumab-atto).*

FDA Label Image

Image (Amjevita 28)

An instructional diagram showing the proper components of a used subcutaneous injection syringe, including the used plunger rod, finger flange, label and expiration date on the syringe barrel, used syringe barrel, used needle, and the needle cap off. The diagram is labeled for clarity.*

FDA Label Image

Image (Amjevita 29)

An instructional illustration showing a hand removing two prefilled syringes from a rectangular package tray. The syringes appear ready for use, consistent with packaging for subcutaneous injection products like AMJEVITA (adalimumab-atto).*

FDA Label Image

Image (Amjevita 30)

An instructional illustration showing hands removing a prefilled injection device from packaging. Two prefilled syringes of AMJEVITA (adalimumab-atto) injection are visible inside the box, with red arrows indicating the direction to pull the syringe out.*

FDA Label Image

Image (Amjevita 31)

An instructional diagram of a pre-filled syringe for AMJEVITA (adalimumab-atto) injection. Labeled parts include needle cap on, syringe barrel, medicine inside the barrel, label and expiration date on the barrel, plunger rod, and finger flange for handling during subcutaneous injection.*

FDA Label Image

Image (Amjevita 32)

Illustration showing medical disposal items associated with injection use: a prefilled syringe with a plunger, a packet labeled AMJEVITA, three cotton balls, an adhesive bandage, and a biohazard sharps container with its lid open, indicating safe disposal practices for subcutaneous injections.*

FDA Label Image

Image (Amjevita 33)

An instructional diagram showing a human figure highlighting recommended subcutaneous injection sites for Amjevita (adalimumab-atto). The stomach area (abdomen) around the navel and the front thighs are marked as suitable injection sites.*

FDA Label Image

Image (Amjevita 34)

Illustration showing the preparation of an injection, where one hand holds the syringe while the other pulls the plunger upward to draw the medication into the syringe. The depiction focuses on proper syringe handling for subcutaneous injection preparation.*

FDA Label Image

Image (Amjevita 35)

An instructional illustration showing a hand pinching the skin on the abdomen to prepare for a subcutaneous injection. The image highlights the proper technique for administering AMJEVITA (adalimumab-atto) injection by subcutaneous route.*

FDA Label Image

Image (Amjevita 36)

An instructional illustration showing a hand administering a subcutaneous injection with a syringe at a 45-degree angle to the skin. The image indicates the proper angle for injection placement relative to the skin surface.*

FDA Label Image

Image (Amjevita 37)

An instructional illustration showing a pair of hands administering a subcutaneous injection using a syringe. One hand is holding the syringe vertically with the needle pointed downward, while the other hand is pinching the skin of the injection site to prepare for the injection.*

FDA Label Image

Image (Amjevita 38)

Instructional illustration showing a hand administering a subcutaneous injection with a syringe into another person's skin. The image emphasizes the upward motion of the syringe during injection.*

FDA Label Image

Image (Amjevita 39)

An instructional illustration showing a hand disposing of a used syringe by placing it into a red biohazard sharps container, indicating safe disposal of injection materials for AMJEVITA (adalimumab-atto) injection.*

FDA Label Image

Principal Display Panel (40 mg Autoinjector Carton)

AMJEVITA 40 mg/0.8 mL subcutaneous injection prefilled autoinjector by Amgen USA Inc. The label features the brand and generic name (adalimumab-atto), dosage strength, and instructions emphasizing cold storage (2°C to 8°C), no freezing, no shaking, and light protection. The product is sterile with no preservative, contains one single-dose autoinjector, and is not made with natural rubber latex. Includes caution to consult accompanying documents and a note that an enclosed medication guide is required.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.